Brief: FDA Approves Atezolizumab For Adjuvant Treatment Of Muscle Invasive Bladder Cancer In Some Patients
15/05/2026 17:46
May 15 (Reuters) - FDA: FDA APPROVES ATEZOLIZUMAB FOR ADJUVANT TREATMENT OF MUSCLE INVASIVE BLADDER CANCER IN PATIENTS WITH MOLECULAR RESIDUAL DISEASE FDA: APPROVES NATERA'S SIGNATERA CDX AS COMPANION DIAGNOSTIC FOR TECENTRIQ BLADDER CANCER TREATMENT FOR SOME PATIENTS - WEBSITE Further company coverage: ROPC.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza